Akebia - AKBA Earnings per share for the last 12 months

Akebia Therapeutics (AKBA) has transitioned to commercial expansion following the approval of its anemia drug. This trailing twelve-month EPS chart on GURU.Markets captures this growth, with the indicator reaching -118.60. Sales diversification across Asia, Europe, and the US minimizes patent risks, while a focus on chronic kidney disease therapies ensures stable supplies to clinics.
Akebia Corp - analytical breakdowns and key metrics (AKBA)

The implementation of energy-saving systems and emission filtration in Akebia Therapeutics (AKBA) laboratories directly impacts operating expenses, affecting the bottom line. The trend in trailing twelve-month (TTM) net income per share measures the efficiency of business scaling amid tight monetary policy, allowing the EPS YoY TTM growth rate chart to diagnose hidden risks of capital stagnation.